pharmaphorum March 18, 2025
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients’ bodies.
The deal includes an initial payment of $425 million when the takeover closes – expected in the second quarter of this year – and another $575 million in future payments tied to the achievement of development and regulatory targets.
EsoBiotec has developed a lentiviral vector platform that can deliver genetic instructions to specific immune cells, such as T cells, and programme them to attack cancer cells or autoreactive cells involved in immune-mediated diseases.
Current cell therapies generally involve harvesting cells from patients, modifying them outside the body and then re-infusing them...
Today's Sponsors
Today's Sponsor